

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	ION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/171,081	12/14/1998		SASA KRANJC	22681-0002 7627			
25213	7590	02/20/2004		EXAM	EXAMINER		
HELLER E		WHITE & MCAU	PRATS, FRANCIS	PRATS, FRANCISCO CHANDLER			
		94025-3506	ART UNIT	PAPER NUMBER			
	,			1651	,		

DATE MAILED: 02/20/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		A 11 A1.	- Na	Applicant(s)				
		''	Application No.					
	Office Action Summany	09/171,08		KRANJC ET AL.	· · · · · · · · · · · · · · · · · · ·			
	Office Action Summary	Examin r		Art Unit				
<u></u> .		Francisco	<u> </u>	1651	<u> </u>			
Period fo	The MAILING DATE of this communic or Reply	ation appears on the	cover sheet with the c	orresp ndence ac	ldress			
THE - Exterent after - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD FO MAILING DATE OF THIS COMMUNIC nsions of time may be available under the provisions of SIX (6) MONTHS from the mailing date of this communic period for reply specified above is less than thirty (30) period for reply is specified above, the maximum stature to reply within the set or extended period for reply wireply received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b).	ATION. 37 CFR 1.136(a). In no evolution of the state of t	ent, however, may a reply be tin utory minimum of thirty (30) day Il expire SIX (6) MONTHS from ication to become ABANDONE	nely filed s will be considered time the mailing date of this c D (35 U.S.C. § 133).	ly. communication.			
Status								
1) 又	Responsive to communication(s) filed	on 22 January 200	4 .					
•—	This action is FINAL . 2b) This action is non-final.							
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposit	ion of Claims							
5)□ 6)⊠ 7)□	Claim(s) 36-38 and 41-55 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. Claim(s) is/are allowed. Claim(s) 36-38 and 41-55 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or election requirement.							
Applicat	ion Papers				•			
10)	The specification is objected to by the The drawing(s) filed on is/are: Applicant may not request that any objection Replacement drawing sheet(s) including the specific states of the specific states o	a) accepted or b) ion to the drawing(s) be the correction is require	e held in abeyance. See ed if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 C				
11)	The oath or declaration is objected to l	by the Examiner. No	te the attached Office	Action or form P	ГО-152.			
Priority (under 35 U.S.C. § 119							
a)	Acknowledgment is made of a claim for All b) Some * c) None of: 1. Certified copies of the priority do according to the priority do according to the certified copies of application from the International See the attached detailed Office action	ocuments have bee ocuments have bee f the priority docume al Bureau (PCT Rul	n received. n received in Applicati ents have been receive e 17.2(a)).	on No ed in this National	Stage			
2) Notice 3) Information	et(s) ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTo- mation Disclosure Statement(s) (PTO-1449 or Per No(s)/Mail Date		4) Interview Summary Paper No(s)/Mail Do 5) Notice of Informal F 6) Other:	ate	O-152)			

Art Unit: 1651

DETAILED ACTION

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on January 22, 2004, has been entered.

Claims 36-38 and 41-55 are pending and are examined on the merits.

Claim Rejections - 35 USC § 102

Claims 36-38, 42-45, 47, 49, 51 and 52 are rejected under 35 U.S.C. 102(b) as being anticipated by Cole et al (U.S. Pat. 4,110,165).

Cole discloses processes of making clavulanic acid wherein the claimed microorganism, Streptomyces clavuligerus, is cultivated in a fermentation medium. Note specifically the potassium dihydrogen phosphate concentration of 0.1% in the fermentation disclosed in Example 13 at column 23. Note further that about 55% of the dipotassium hydrogen phosphate in the fermentation medium in Example 9, at column 21, is "assimilable"

Art Unit: 1651

phosphorus, i.e. phosphate, and that therefore the medium in Example 9 contains about 1.10 grams of assimilable phosphorus per liter of medium which is about 0.11% assimilable phosphorus, well within the claimed range concentration. Therefore, in at least Examples 9 and 13, the starting phosphorus concentration is below the claimed amount. Moreover, no phosphorus is added during the fermentation, and the fermentations last for 3-5 days. Thus, the processes disclosed in Examples 9 and 13 necessarily meet the limitation requiring the microorganism to be grown within the claimed phosphorus concentration range, and also meet the limitation requiring a decrease in the phosphorus concentration. Moreover Example 9 uses "Arkasoy," or soy flour as the nitrogen source. See column 20, lines 1 and 2. A holding of anticipation over the cited claims is therefore required.

Claim Rejections - 35 USC § 103

Claims 36-38, 41-47 and 49-54 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cole et al (U.S. Pat. 4,110,165).

As discussed above, Cole is considered to anticipate claims 36-38, 42-45, 47, 49, 51 and 52, because Cole discloses processes of making clavulanic acid wherein the claimed

Art Unit: 1651

microorganism, Streptomyces clavuligerus, is cultivated in a fermentation medium containing the claimed amounts of nutrients, including phosphate.

Cole differs from the claims in that Cole does not explicitly disclose processes wherein the phosphorus concentration is about 0.008%, as recited in claim 41. Cole discloses the desirability of phosphate in the fermentation media used therein. Moreover, nutrient concentrations in fermentation media are result-effective parameters whose values are determined through routine experimentation by artisans of Therefore, the determination of suitable ordinary skill. phosphate concentrations, such as recited in claim 41, must be considered prima facie obvious absent some demonstration of an unexpected result coming from the use of that concentration. The range of carbon source concentrations recited in claim 50 must also be considered obvious for similar reasons, particularly in view of Coles's explicit disclosure of carbon source concentrations encompassing a significant portion of the values recited in applicant's claims. See column 10, lines 39-42.

Also, the use of sodium dihydrogen phosphate as the phosphorus source, recited in claim 46, must be considered obvious over Cole's disclosed use of potassium dihydrogen

Art Unit: 1651

phosphate as the phosphorus source, the artisan of ordinary skill reasonably expecting the salts of potassium and sodium to function substantially equivalently in the processes disclosed by Cole, especially in view of Cole's disclosure that either of the salts of phosphoric acid may be used. See column 10, lines 56-57. Lastly, the use of large volume fermentations in the processes disclosed by Cole, recited in claims 53 and 54, must be considered obvious, in view of the fact that it would have been economically desirable to have produced larger quantities of the desired compound. A holding of obviousness over the cited claims is required.

Claims 36-38 and 41-55 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cole et al (U.S. Pat. 4,110,165) in view of Stanbury et al (*Principles of Fermentation Technology*, Pergamon Press, New York, 1984, pages 11-25).

As discussed above, Cole is considered to anticipate claims 36-38, 42-45, 47, 49, 51 and 52, and to render obvious claims 36-38, 41-47 and 49-54. Cole does not explicitly disclose conducting the fermentations as fed-batch or continuous processes, as recited in claims 48 and 55. However, Cole clearly discloses that 0.1% is a suitable concentration of phosphorus for fermentative production of clavulanic acid. See

Page 6

Application/Control Number: 09/171,081

Art Unit: 1651

Example 13. Thus, the artisan of ordinary skill at the time of applicant's invention clearly would have been motivated by Cole's disclosure of the suitability of 0.1% phosphorus to have ensured the presence of that amount of phosphorus, in continuous or fed-batch processes of the type disclosed by Stanbury. Additional motivation for using the fed-batch systems disclosed by Stanbury would have been derived from the fact that clavulanic acid is a very similar molecule to penicillin, and Stanbury discloses that fed-batch processes are particularly desirable in fermentations which produce antibiotics such as penicillin. See Stanbury at 23, discussing the applicability of fed-batch fermentation to penicillin production. A holding of obviousness over the cited claims is therefore required.

Claims 36-38 and 41-55 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cole et al (U.S. Pat. 4,110,165) in view of Stanbury et al (*Principles of Fermentation Technology*, Pergamon Press, New York, 1984, pages 11-25), as applied above to claims 36-38 and 41-55, and in further view of Puentes et al (EP 0 182 522 A1).

As discussed above, Cole obviates claims 36-38 and 41-55 when taken in view of Stanbury. With the exception of Streptomyces clavuligerus, neither of those references discloses

Art Unit: 1651

the production of clavulanic acid from all of the microorganisms recited in claim 47. However, Puentes et al disclose that all of the claimed microorganisms were known at the time of applicant's invention to produce clavulanic acid in known media containing carbon sources, nitrogen sources and inorganic salts. See page 2. Thus, the substitution of any known clavulanic acid-producing species for that disclosed in Cole clearly would have been considered an obvious matter of selecting from known equivalents, the artisan of ordinary skill reasonably expecting from Puentes that the microorganisms disclosed therein would be able to produce clavulanic acid in the fermentation media disclosed by Cole. Thus, absent some unexpected result inhering from the use of the claimed microorganisms, the claims must be considered obvious in this respect.

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Francisco C Prats whose telephone number is 571-272-0921. The examiner can normally be reached on Monday through Friday, with alternate Fridays off.

Application/Control Number: 09/171,081 Page 8

Art Unit: 1651

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (to)1-free).

Francisco C Prats Primary Examiner Art Unit 1651

FCP